Physician profile
Claire Fahey
NPI 1073349056
$4,120.88
in general payments reported to CMS, 2019-2025
24 companies · $3,661 in 2025
The $3,661 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $460 · 2025: $3,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,120.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $619.20 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $440.92 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $328.49 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $285.92 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.91 | 2024-2025 | Jardiance |
| Pfizer INC. | $258.13 | 2024-2025 | |
| Abbvie INC. | $224.71 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $221.51 | 2024-2025 | |
| Lilly USA, LLC | $217.85 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $202.99 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $179.09 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.16 | 2025 | Caplyta |
| Edwards Lifesciences Corporation | $104.04 | 2025 | Sapien 3 Ultra Resilia |
| Axsome Therapeutics, INC. | $102.34 | 2025 | Auvelity |
| Recor Medical INC | $91.24 | 2025 | Paradise Ultrasound Renal Denervation System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $78.10 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $68.39 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Abbott Laboratories | $65.12 | 2024-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $56.13 | 2025 | |
| Amgen INC. | $49.42 | 2025 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $45.43 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $44.59 | 2025 | Zoryve |
| Verona Pharma, INC. | $31.97 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $21.23 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Fahey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.